Novavax

Novavax, Inc. focuses on the discovery, development and commercialization of vaccines to prevent infectious diseases. It provides vaccines for COVID-19, seasonal flu, respiratory syncytial virus, Ebola, and Middle East respiratory syndrome. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Novavax reports strong revenue growth, focuses on fall vaccine launch

Novavax aims to deliver a competitive vaccine for the fall season, optimize cash flow, and mitigate risks. The company's focus on cost reduction and strategic investments align with its goal of long-term growth.

Novavax reports positive Phase 2 results and revenue guidance

Novavax's Q1 2023 earnings call highlighted positive Phase 2 trial results, revenue guidance, and cost-saving initiatives.
The company's focus on vaccine development, workforce reductions, and strategic collaborations bode well for future growth.
Challenges include ongoing arbitration with Gavi and managing global restructuring impacts on R&D efforts.
Opportunities lie in revenue growth, market expansion with Nuvaxovid, and leveraging technology for a robust vaccine portfolio.

Novavax reports robust Q2 earnings, anticipates strong revenue growth

Novavax is on track to deliver an updated vaccine for the fall season and expects strong revenue growth in 2023. They have significantly reduced liabilities, signed key agreements, and are investing in combination vaccines. Despite challenges ahead, the company remains committed to delivering successful performance.

Novavax reports strong Q3 results, eyes market share growth

Novavax is strategically positioned to drive long-term profitability with efficient cost structures.
The company's focus on innovation, cost reduction, and market expansion bodes well for future growth.
Despite challenges, Novavax's strong financial position and technology platform offer resilience and growth opportunities.

Novavax reduces expenses, targets growth with new vaccines in 2024

Novavax made significant strides in reducing expenses and liabilities in 2023, positioning for growth in 2024.
The company's focus on advancing its combination vaccine program and improving market share presents opportunities for expansion.
Challenges include improving U.S. market performance, addressing remaining liabilities, and securing regulatory authorizations.
Efforts to streamline operations, enhance customer engagement, and offer convenient products are key to Novavax's success in 2024.

Novavax reports strong Q1 earnings, secures $1.3B Sanofi deal

Novavax's Q1 2024 performance shows promising revenue growth, expense reduction, and strategic partnership with Sanofi driving cash flow improvements.
While facing challenges in managing the multibillion-dollar opportunity and regulatory pathways, Novavax is well-positioned to capitalize on revenue opportunities.
The company's focus on optimizing existing agreements, expanding partnerships, and exploring new areas like RSV sets a strong foundation for future growth.

Novavax reports $85M revenue, focuses on cost reduction and partnerships

Novavax's Q3 2024 performance showcased revenue growth and strategic cost reduction efforts.
Key strengths include a strong partnership with Sanofi and a focus on pipeline development.
Challenges ahead involve cost alignment, trial design complexities, and maintaining margins.
Opportunities lie in new pipeline programs, financial gains from partnerships, and cost optimization.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Novavax, Inc. Is a biotechnology company, which engages in the discovery, development, and commercialization of recombinant vaccines. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

Novavax's prospects depend on the company resolving its manufacturing issues.

What's the Outlook for Novavax Stock?

Jazz Pharmaceuticals

Viatris

Analysts are bullish about these bargains.

3 Dirt-Cheap Stocks Wall Street Thinks Will Soar 43% to 80%

BioNTech SE

RedHill Biopharma

Why BioNTech and RedHill Are Soaring This Week, While Novavax Is Sinking

Novavax (NVAX) closed the most recent trading day at $138.79, moving +1.41% from the previous trading session.

Novavax (NVAX) Outpaces Stock Market Gains: What You Should Know

LOS ANGELES--(BUSINESS WIRE)---- $NVAX #CLASSACTION--Glancy Prongay & Murray LLP (“GPM”), a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Novavax, Inc. (“Novavax” or the “Company”) (NASDAQ: NVAX) investors concerning the Company's possible violations of the federal securities laws. If you suffered a loss on your Novavax investments or would like to inquire about potentially pursuing claims to recover your loss under the federal securities laws, y

Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Novavax, Inc. (NVAX) on Behalf of Investors

Boston, Massachusetts--(Newsfile Corp. - October 21, 2021) - Berman Tabacco, a national law firm representing investors, is investigating potential securities law violations by Novavax, Inc. ("Novavax" or the "Company") (NASDAQ: NVAX), a biotechnology company with headquarters in Gaithersburg, Maryland. Novavax purports to be "conducting late-stage clinical trials for NVX-CoV2373, its vaccine candidate against SARS-CoV-2, the virus that causes COVID-19."On October 19, 2021, after the market closed, Politico published an article, entitled "'They Rushed...

NVAX Alert: Berman Tabacco Announces Investigation of Novavax, Inc. for Potential Securities Law Violations

Novavax's (NVAX) shares fall on reports of the company's manufacturing problems related to its COVID-19 vaccine candidate.

Novavax (NVAX) Down on COVID Jab-Manufacturing Problem Reports

New York, New York--(Newsfile Corp. - October 21, 2021) - ATTENTION NVAX INVESTORS:The Gross Law Firm is investigating Novavax, Inc. ("Novavax" or the "Company") (NASDAQ: NVAX) concerning possible violations of federal securities laws. Register your information here for more details about the investigation:https://securitiesclasslaw.com/securities/novavax-inc-loss-submission-form/The investigation concerns allegations relating to manufacturing and purity problems in Novavax's process to produce COVID-19 vaccinations, particularly the allegations contained in an article titled, "'They Rushed the Process': Vaccine Maker's woes hamper...

NVAX ALERT: The Gross Law Firm Investigates Possible Securities Fraud Violations by Novavax, Inc.

The FDA approval is a near term catalyst that will take NVAX stock to new highs over the coming months. Buy NVAX stock in the dip.

While Much Riding on FDA Nod, Novavax Fortunes Are More Than Just Covid

The advantages that Novavax offers are obvious.

7 Reasons Why Novavax Is a No-Brainer Pick Over Ocugen

FuboTV

Redfin

Trulieve Cannabis Corp.

These innovative companies can deliver eye-popping revenue growth over the next four years.

4 Supercharged Growth Stocks Expected to Increase Sales 306% to 658% by 2024

Advanced Micro Devices

Netflix

Wish

Advanced Micro Devices, Netflix, ContextLogic and Novavax were our top stock trades for Thursday. Now, here's what the charts are saying.

4 Top Stock Trades for Thursday: AMD, NFLX, WISH, NVAX

New York, New York--(Newsfile Corp. - October 20, 2021) - Wolf Popper LLP is investigating potential securities fraud claims on behalf of purchasers of Novavax, Inc. (NASDAQ: NVAX) common stock.Novavax is a clinical-stage drug company that has been developing NVX-CoV2373, its COVID-19 vaccine. On July 7, 2021, Novavax announced it had been selected to participate in Operation Warp Speed and was awarded $1.6 billion by the federal government to complete late-stage clinical development, including...

Wolf Popper LLP Announces Investigation on Behalf of Purchasers of Novavax, Inc. (NVAX) Common Stock

Novavax said it remains confident in its ability to bring a Covid-19 vaccine to market after shares plunged 20% Wednesday morning.

Novavax Stock Plunges As Manufacturing Problems Reportedly Imperil The Firm's Covid-19 Vaccine

Novavax Inc. (NASDAQ:NVAX) shares are trading lower Wednesday following a report suggesting the company is facing issues with the purity of its COVID-19 vaccine candidate. The company has been unable to consistently manufacture a shot that meets the quality standards.

Novavax Cracks Below Support: Are Things Getting Ugly?

NVAX stock is struggling on Wednesday as investors process what's going on behind the scenes with Novavax's manufacturing. The post NVAX Stock: The Huge Reason Novavax Is Plunging Today appeared first on InvestorPlace.

NVAX Stock: The Huge Reason Novavax Is Plunging Today

NEW YORK--(BUSINESS WIRE)--WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Novavax, Inc. (NASDAQ: NVAX) resulting from allegations that Novavax may have issued materially misleading business information to the investing public. SO WHAT: If you purchased Novavax securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. The R

EQUITY ALERT: Rosen Law Firm Encourages Novavax, Inc. Investors with Losses to Inquire About Class Action Investigation – NVAX

The potential production problems with Novavax's vaccine could hamper the efforts of the COVAX initiative, which forecast in September that it will be able to provide low and middle-income countries 1.425 billion COVID-19 vaccine doses to by the end of the year and 2 billion doses by the first quarter of 2022.

Novavax stock tanks on report of COVID-19 vaccine manufacturing troubles

Politico reported that the company's manufacturing issues are worse than initially thought.

Why Novavax Stock Is Tanking Today

Biotechnology name Novavax, Inc.  (NASDAQ:NVAX) is plummeting this morning, last seen down 18.3% to trade a $131.18.

Novavax Stock Nosedives on Vaccine Production Delays

Brinker International

Brinker and Novavax are down big in premarket trading as investors try to sort through numerous earnings announcements

Netflix, Brinker, And Novavax Are Making Headlines

Shares of Novavax Inc (NASDAQ: NVAX) opened about 25% down this morning on a report that the biotech firm continues to struggle in manufacturing its COVID-19 vaccine at scale. Novavax is yet to secure emergency use authorisation Earlier this year, Novavax said its vaccine showed 93% efficacy against the Coronavirus.

Novavax shares opened 25% down on Wednesday: what happened?

While NVAX stock had an excellent run, the vaccination market is practically saturated, meaning investors should consider profit-taking. The post It's Time to Secure Those Profits You Earned from Novavax appeared first on InvestorPlace.

It's Time to Secure Those Profits You Earned from Novavax

Shares of Novavax Inc fell 20% after a report from Politico said the company faces significant hurdles in proving it can manufacture its experimental COVID-19 vaccine that meets regulators' quality standards, resulting in production delays.

Novavax tumbles after Politico report on COVID-19 vaccine production delay

A report says Novavax has failed to produce a vaccine with the purity levels demanded by the Food and Drug Administration.

News for Novavax Stock (NVAX)